Chronic myelogenous leukemia: Laboratory diagnosis and monitoring

Genes Chromosomes and Cancer

Volumn 32, Issue 2, 2001, Pages 97-111

  Lynn Wang, Y ^a   Bagg, A ^a   Pear, Warren ^a   Nowell, Peter C ^a   Hess, Jay L ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COST BENEFIT ANALYSIS; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; KARYOTYPING; LABORATORY DIAGNOSIS; LABORATORY TEST; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STEM CELL TRANSPLANTATION;

CYTOGENETIC ANALYSIS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID, CHRONIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0034842032     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.1171     Document Type: Review

References (119)

1. BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion
2. Clinical, morphological, cytogenetic and molecular aspects of a series of Ph-negative chronic myeloid leukemias
3. Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients
4. Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization
5. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals
6. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease
7. Monitoring chronic mycloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics
8. Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon alpha therapy?
9. A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia
10. Complex translocations of the Ph chromosome and Ph negative CML arise from similar mechanisms, as evidenced by FISH analysis
11. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation
12. Marrow transplantation for CML: The Seattle experience
13. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results
14. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation
15. Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: Comparison with metaphase banding analysis
16. Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol)
17. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia
18. The application of fluorescent in situ hybridization to detect Mbcr/abl fusion in variant Ph chromosomes in CML and ALL
19. Highly sensitive fluorescence in situ hybridization method to detect double BGR/ABL fusion and monitor response to therapy in chronic myeloid leukemia
20. Minimal residual disease in interferon-treated chronic myelogenous leukemia: Results and pitfalls of analysis based on polymerase chain reaction
21. Detection of BCR/ABL RNA transcripts using the polymerase chain reaction is highly predictive for relapse in patients transplanted with unrelated marrow grafts for chronic myelogenous leukaemia
22. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
23. Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
24. Monitoring of remission status by fluorescence in situ hybridisation in chronic myeloid leukaemia patients treated with interferon-alpha
25. Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation
26. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage
27. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR
28. A Ph-negative chronic myeloid leukemia patient with a non-classical BCR-ABL rearrangement characterized by fluorescence in situ hybridization
29. Chronic myelogenous leukemia: Biology and therapy
30. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
31. Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT)
32. Detection of the Mbcr/abl translocation in chronic myeloid leukemia by fluorescence in situ hybridization: Comparison with conventional cytogenetics and implications for minimal residual disease detection
33. Growth factor independence and BCR/ABL transformation: Promise and pitfalls of murine model systems and assays
34. Cytogenetics, in situ hybridization and molecular approaches in the diagnosis of cancer
35. A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia
36. Allogeneic bone marrow transplantation for chronic myeloid leukemia
37. Comparative analysis of G-banding, chromosome painting, locusspecific fluorescence in situ hybridization, and comparative genomic hybridization in chronic myeloid leukemia blast crisis
38. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
39. Multiplex fluorescence in situ hybridization and cross species color banding of a case of chronic myeloid leukemia in blastic crisis with a complex Philadelphia translocation
40. P230 BCR/ ABL protein may be associated with an acute leukaemia phenotype
41. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia
42. Detection of chromosomal translocations in leukemia. Is there a best way?
43. Response of chronic myelogenous leukemia patients to COAP-splenectomy
44. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction
45. A novel BCR-ABL fusion gene (c6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia
46. A phase II study to determine the safety and anti-leukemic effects of STI 571 in patients with Philadelphia chromosome positive chronic meyloid leukemia in myeloid blast crisis
47. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: Low levels of minimal residual disease are associated with continuing remission
48. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: Role of polymerase chain reaction in predicting relapse
49. Heterogeneity of the breakpoint in the ABL gene in cases with BCR/ABL transcript lacking ABL exon a2
50. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients
51. Characteristics of accelerated disease in chronic myelogenous leukemia
52. Chronic myelogenous leukemia: A concise update
53. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy
54. Phase II study of STI 571, a tyrosine kinase inhibitor, in patients with resistant or refractory Philadelphia chromosome positive chronic meyloid leukemia
55. Unusual expression of mRNA typical of Philadelphia positive acute lymphoblastic leukemia detected in chronic myeloid leukemia
56. Fluorescence in situ hybridization studies of interphase nuclei for assessing response to therapy in patients with chronic myeloid leukemia
57. Additional translocation (8;21)(q22;q22) in a patient with Philadelphia-positive chronic myelogenous leukaemia in the blastic phase
58. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
59. Light-Cycler technology for the quantitation of bcr/abl fusion transcripts
60. Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: A chronic myeloid leukemia with a distinct clinical course
61. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity
62. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy
63. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia
64. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation
65. Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia
66. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction
67. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia
68. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon
69. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
70. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia
71. Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha
72. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia
73. Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy
74. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype
75. BCR-ABL gene variants
76. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR
77. Simple competitive two-step RT-PCR assay to monitor minimal residual disease in CML patients after bone marrow transplantation
78. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: A new strategy for remission assessment
79. Philadelphia-negative chronic myeloid leukaemia: Detection by FISH of BCR-ABL fusion gene localized either to chromosome 9 or chromosome 22
80. Karyotypic findings as an independent prognostic marker in chronic myeloid leukaemia blast crisis
81. A minute chromosome in chronic granulocytic leukemia
82. Molecular background of a new case of chronic myelogenous leukemia with bcr-abl chimera mRNA lacking the A2 exon
83. Neutrophilicchronic myeloid leukemia: A distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)
84. Monitoring the response of CML patients treated with STI 571 by molecular cytogenetics and quantitative RT-PCR
85. An acceleratedphase CML patient with e19a2 junction of BCR/ABL gene - The first case of transplanted CML with micro bcr
86. The graft-versus-leukemia effects of allogeneic cell therapy
87. Polymcrase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: Results and implications in 346 patients
88. BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-alpha
89. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia
90. p190 bcr-abl rearrangement: A secondary cytogenetic event in some chronic myeloid disorders?
91. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
92. New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myclogenous leukemia
93. Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis
94. Chronic myeloid leukemia
95. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
96. Chronic myelogenous leukemia with typical clinical and morphological features can be Philadelphia chromosome negative and "bcr negative"
97. Analysis of interphase cells for the Philadelphia translocation using painting probe made by inter-Alu-polymerase chain reaction from a radiation hybrid
98. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment
99. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
100. Improved sensitivity of BCR-ABL detection: A triple-probe three-color fluorescence in situ hybridization system
101. Chromosomal aberrations during progression of chronic myeloid leukemia identified by cyrogenetic and molecular cytogenctic tools: Implication of 1q12-q21
102. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients
103. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies
104. A phase II study of STI 571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase
105. Chronic myeloid leukemia from basics to bedside
106. Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation
107. Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization
108. Molecular beacons: Probes that fluoresce upon hybridization
109. bcr-abl mRNA lacking abl exon a2 detected by polymerase chain reaction in a chronic myelogeneous leukemia patient
110. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias
111. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: A report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
112. Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia
113. Molecular pathogenesis of chronic myeloid leukemia: Implications for new therapeutic strategies
114. Value of fluorescence in situ hybridization for detecting the bcr/abl gene fusion in interphase cells of routine bone marrow specimens
115. Continuous fluorescence monitoring of rapid cycle DNA amplification
116. Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells
117. Clinical implications of fluorescence in situ hybridization analysis in 13 chronic myeloid leukemia cases: Ph-negative and variant Ph-positive
118. Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia